ABSTRACT
Objective To investigate the clinical efficacy of chemical therapy with or without Endostar treatment for late‐stage non‐small cell lung cancer (NSCLC) with the expression of excision repair cross‐complementing group 1 (ERCC1) .Methods Three hundred and one NSCLC patients of IV stage from 2012 June to 2013 June were enrolled in our hospital and the expression of ERCC1 was detected by immunohistochemical staining in tissue samples ,then the patients were divided into chemotherapy alone group and chemotherapy with Endostar group ,the recent curative effect and patients′survival in two groups were evaluated .Results Among 301 NSCLC patients ,166 patients had a positive expression of ERCC1 and account to 55 .1% .The efficacy rate in ERCC1+ NSCLC patients was significantly lower than that in ERCC1‐NSCLC patients .In ERCC1+ NSCLC patients ,compared with the chemotherapy alone group ,the response rate in the chemotherapy with Endostar group was increased ,and the median survival time (MST) and median time to progress(TTP) were also extended .Conclusion chemotherapy with Endostar increased the recent cura‐tive effect of NSCLC patients and might conducive to improving the quality of life .
ABSTRACT
Excision repair cross complementing group 1 (ERCC1) gene is an enzyme of the speed limit of DNA repair protein in nucleotide excision repair (NER) pathways.Researches suggest that ERCC1 has been associated with cisplatin resistance in non-small cell lung cancer (NSCLC) patients.Thus,ERCC1 gene is a new target in malignant tumor gene therapy research,providing a new approach for the treatment of malignant,especially NSCLC.